Back to results
US 2025/0375474 A1Published application
Compositions for the prevention and treatment of moisture-associated skin damage
AssigneesJohanna MERCER, Scotiaderm Inc.
InventorAnn GORDON
Life of this patent
Estimating the term…
Abstract
Therapeutic compositions, kits, and methods and uses thereof are provided. The compositions comprise zinc oxide, hydrocortisone, and/or clotrimazole.
Claims35
A therapeutic composition comprising:
- from about 10% to about 15% by weight zinc oxide;
- 1% by weight hydrocortisone;
- from about 0.5% to about 1% by weight clotrimazole;
- optionally from about 40% to 50% by weight petrolatum;
- optionally from about 0.01% to about 2.5% by weight dimethicone;
- and
- optionally about 0.1-30% by weight a proteolytic enzyme inhibitor, preferably the proteolytic enzyme inhibitor is a trypsin inhibitor.
4 more elements
-17. (canceled)
(canceled)
-23. (canceled)
A kit comprising:
- optionally a first composition preferably being a first cream comprising non-medicated ingredients for skin protection;
- a second composition preferably being a second cream comprising 0.1-1.1% by weight hydrocortisone and optionally zinc oxide;
- a third composition preferably being a third cream comprising 0.1-1.1% by weight clotrimazole and optionally zinc oxide;
- and
- optionally a fourth composition preferably being a fourth cream comprising one or more of a pH buffer, a moisturizing agent or humectant, an antimicrobial agent, or an antifungal agent;
- wherein optionally one or more of the first, second, third and fourth cream comprise a proteolytic enzyme inhibitor.
3 more elements
-26. (canceled)
-30. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-50. (canceled)
A composition comprising a trypsin inhibitor and a carrier, for prevention or treatment of moisture-associated skin damage (MASD).
A composition comprising a trypsin inhibitor and a carrier, for inhibiting fecal enzymes on a skin of a subject.
Dependencies are inferred from the claim text.